Abstract
Despite advances in early diagnosis, prevention, and treatment, breast cancer remains the second-leading cause of cancer-related deaths in women. The 5-year survival rate for patients with metastatic breast cancer (MBC) is just 24%. However, some forms of MBC appear to be more aggressive than others. Triple-negative breast cancer (TNBC; lacking overexpression of human epidermal growth factor receptor 2 [HER2] and expression of estrogen and progesterone receptors) and breast cancers that overexpress HER2 are the 2 biologically defined subtypes with the worst prognoses. Although a number of effective options have been developed for the treatment of HER2-overexpressing disease, TNBC remains a difficult-to-treat subtype. In addition to hormone receptor and HER2 status, multiple other factors are predictive of relatively poorer clinical outcomes, including visceral metastasis, short disease-free interval between the end of treatment for early-stage disease and diagnosis of MBC, and higher number of metastatic sites. There is an urgent need to improve therapy for patients with aggressive forms of breast cancer. Taxanes are considered among the most active classes of compounds against breast cancer. This review specifically examines the clinical trials in which nab-paclitaxel was used to treat patients with MBC and factors associated with poor prognosis.
| Original language | English |
|---|---|
| Pages (from-to) | 221-227 |
| Number of pages | 7 |
| Journal | Clinical Breast Cancer |
| Volume | 14 |
| Issue number | 4 |
| DOIs | |
| State | Published - Jan 1 2014 |
| Externally published | Yes |
Fingerprint
Keywords
- Aggressive
- Metastatic breast cancer
- nab-Paclitaxel
- Poor prognosis
- Triple-negative breast cancer
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Nab-paclitaxel for the treatment of aggressive metastatic breast cancer. / Glück, Stefan.
In: Clinical Breast Cancer, Vol. 14, No. 4, 01.01.2014, p. 221-227.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nab-paclitaxel for the treatment of aggressive metastatic breast cancer
AU - Glück, Stefan
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Despite advances in early diagnosis, prevention, and treatment, breast cancer remains the second-leading cause of cancer-related deaths in women. The 5-year survival rate for patients with metastatic breast cancer (MBC) is just 24%. However, some forms of MBC appear to be more aggressive than others. Triple-negative breast cancer (TNBC; lacking overexpression of human epidermal growth factor receptor 2 [HER2] and expression of estrogen and progesterone receptors) and breast cancers that overexpress HER2 are the 2 biologically defined subtypes with the worst prognoses. Although a number of effective options have been developed for the treatment of HER2-overexpressing disease, TNBC remains a difficult-to-treat subtype. In addition to hormone receptor and HER2 status, multiple other factors are predictive of relatively poorer clinical outcomes, including visceral metastasis, short disease-free interval between the end of treatment for early-stage disease and diagnosis of MBC, and higher number of metastatic sites. There is an urgent need to improve therapy for patients with aggressive forms of breast cancer. Taxanes are considered among the most active classes of compounds against breast cancer. This review specifically examines the clinical trials in which nab-paclitaxel was used to treat patients with MBC and factors associated with poor prognosis.
AB - Despite advances in early diagnosis, prevention, and treatment, breast cancer remains the second-leading cause of cancer-related deaths in women. The 5-year survival rate for patients with metastatic breast cancer (MBC) is just 24%. However, some forms of MBC appear to be more aggressive than others. Triple-negative breast cancer (TNBC; lacking overexpression of human epidermal growth factor receptor 2 [HER2] and expression of estrogen and progesterone receptors) and breast cancers that overexpress HER2 are the 2 biologically defined subtypes with the worst prognoses. Although a number of effective options have been developed for the treatment of HER2-overexpressing disease, TNBC remains a difficult-to-treat subtype. In addition to hormone receptor and HER2 status, multiple other factors are predictive of relatively poorer clinical outcomes, including visceral metastasis, short disease-free interval between the end of treatment for early-stage disease and diagnosis of MBC, and higher number of metastatic sites. There is an urgent need to improve therapy for patients with aggressive forms of breast cancer. Taxanes are considered among the most active classes of compounds against breast cancer. This review specifically examines the clinical trials in which nab-paclitaxel was used to treat patients with MBC and factors associated with poor prognosis.
KW - Aggressive
KW - Metastatic breast cancer
KW - nab-Paclitaxel
KW - Poor prognosis
KW - Triple-negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=84904653755&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904653755&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2014.02.001
DO - 10.1016/j.clbc.2014.02.001
M3 - Article
C2 - 24806278
AN - SCOPUS:84904653755
VL - 14
SP - 221
EP - 227
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
SN - 1526-8209
IS - 4
ER -